What’s Next for CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) After Having More Shares Shorted?

January 14, 2018 - By Ellis Scott

Investors sentiment increased to 8 in Q3 2017. Its up 7.00, from 1 in 2017Q2. It is positive, as 2 investors sold Cannabis Science, Inc. shares while 0 reduced holdings. 0 funds opened positions while 1 raised stakes. 304,780 shares or 15.15% less from 359,180 shares in 2017Q2 were reported.
Stonebridge Cap Ltd Llc holds 0% or 10,000 shares in its portfolio. Rothschild Inv Corp Il invested in 0% or 14,000 shares. North Star Asset Mgmt has 0% invested in Cannabis Science, Inc. (OTCMKTS:CBIS) for 40,000 shares. Donaldson Capital Mngmt Limited Liability Company, a Indiana-based fund reported 99,780 shares. Frontier Invest Management holds 0% of its portfolio in Cannabis Science, Inc. (OTCMKTS:CBIS) for 20,000 shares. Oxbow Advsrs Limited Liability Com has 0% invested in Cannabis Science, Inc. (OTCMKTS:CBIS). Neville Rodie & Shaw has 0% invested in Cannabis Science, Inc. (OTCMKTS:CBIS) for 95,000 shares. Toth Advisory Corporation holds 0% of its portfolio in Cannabis Science, Inc. (OTCMKTS:CBIS) for 11,000 shares.

The stock of CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) registered an increase of 4496.67% in short interest. CBIS’s total short interest was 689,500 shares in January as published by FINRA. Its up 4496.67% from 15,000 shares, reported previously.

The stock decreased 1.37% or $0.00137 during the last trading session, reaching $0.09863. About 29.72 million shares traded. Cannabis Science, Inc. (OTCMKTS:CBIS) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid pharmaceutical products primarily in the United States. The company has market cap of $251.69 million. The firm is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. It currently has negative earnings. The Company’s drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis therapy for neurological conditions.

More notable recent Cannabis Science, Inc. (OTCMKTS:CBIS) news were published by: Globenewswire.com which released: “Cannabis Science Negotiates for Major Asset Backed Blockchain Crypto Currency …” on December 22, 2017, also Globenewswire.com with their article: “Cannabis Science Prepares for the Grand Opening of Its First Two Pre ICO …” published on January 08, 2018, Globenewswire.com published: “Cannabis Science Actively Pursuing US Federal Government Contracts and Is …” on January 09, 2018. More interesting news about Cannabis Science, Inc. (OTCMKTS:CBIS) were released by: Globenewswire.com and their article: “Cannabis Science Acquires Second PRE ICO Dispensary” published on December 20, 2017 as well as Globenewswire.com‘s news article titled: “Cannabis Science Negotiates With Crown Baus Capital Corp (OTC: CBCA) for …” with publication date: January 03, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.